D
Biohaven Ltd. BHVN
$30.40 -$0.57-1.84%
Recommendation
Sell
Prev Close
$30.97
Volume
1,377,990
Avg Vol (90D)
936,004
Market Cap
$3.16B
Dividend & Yield
--
52-Week Range
$26.80 - $62.21
P/E (TTM)
--
EPS (TTM)
-$9.39
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
JPMorgan Chase & Co. Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price
3/6/2025 - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Director Purchases $996,369.00 in Stock
3/6/2025 - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Director John W. Childs Buys 32,700 Shares
3/6/2025 - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Biohaven (NYSE:BHVN)
3/5/2025 - MarketBeat
Video: Wednesday 3/5 Insider Buying Report: GO, BHVN
3/5/2025 - Market News Video
The Implied Analyst 12-Month Target For VB
3/5/2025 - ETF Channel
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3/5/2025 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3/5/2025 - PR Newswire
Biohaven (NYSE:BHVN) Given Outperform Rating at Royal Bank of Canada
3/4/2025 - MarketBeat
Y Intercept Hong Kong Ltd Has $315,000 Holdings in Biohaven Ltd. (NYSE:BHVN)
3/4/2025 - MarketBeat
Company News for Mar 4, 2025
3/4/2025 - Zacks Investment Research
Biohaven (NYSE:BHVN) Shares Down 6.1% Following Weak Earnings
3/3/2025 - MarketBeat
Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.29 EPS
3/3/2025 - MarketBeat
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG ...
3/3/2025 - GuruFocus
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial ...
3/3/2025 - GuruFocus
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
3/3/2025 - PR Newswire
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
3/3/2025 - PR Newswire
Peregrine Capital Management LLC Makes New $5.56 Million Investment in Biohaven Ltd. (NYSE:BHVN)
2/19/2025 - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Sees Large Decrease in Short Interest
2/18/2025 - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Buy" from Analysts
2/15/2025 - MarketBeat
Why Biohaven (BHVN) Stock Is Rallying Today
2/11/2025 - Insider Monkey
Biohaven (BHVN) Shares Cross Above 200 DMA
2/11/2025 - Market News Video
Biohaven (NYSE:BHVN) Shares Gap Up - What's Next?
2/11/2025 - MarketBeat
Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for ...
2/11/2025 - GuruFocus
Deutsche Bank Aktiengesellschaft Initiates Coverage on Biohaven (NYSE:BHVN)
2/11/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$866.36M
EBIT (TTM)
-$874.21M
Net Income (TTM)
-$846.42M
Balance Sheet
Total Assets (Q)
$615.11M
Total Debt (Q)
$36.58M
Total Liabilities (Q)
$191.67M
Book Value Per Share (Q)
$4.18
Cash Flow
Cash from Operations (TTM)
-$582.45M
Cash from Investing (TTM)
-$244.97M
Cash from Financing (TTM)
$677.77M
Net Change in Cash (TTM)
-$149.58M
Filings
Filing Date
Monday, March 3, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.49
7-Day Total Return
-16.55%
30-Day Total Return
-25.05%
60-Day Total Return
-30.10%
90-Day Total Return
-42.37%
Year to Date Total Return
-18.46%
1-Year Total Return
-47.70%
2-Year Total Return
113.78%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
May 29, 2024 - $26.80
52-week High
Mar 08, 2024 - $62.21
Valuation
Market Cap
$3.16B - Mid Cap
Enterprise Value
$2.71B
Price/Sales (TTM)
--
Price/Book (Q)
7.40
Dividends and Shares
Shares Outstanding
101.05M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biohaven.com
Phone Number
203 404 0410
Address
215 Church Street
New Haven, CT 06510
Country
United States
Year Founded
2022
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company’s pipeline... more
NYSE 03/06/2025 4:00PM Eastern Quotes delayed
Weiss Ratings